4786
M. K. Ghorai et al. / Tetrahedron 63 (2007) 4779–4787
CH3Si), 0.02 (3H, s, CH3Si), 0.85 (9H, s, t-BuSi), 1.32–1.77
(4H, m, (CH2)a, (CH2)b), 2.31 (3H, s, ArCH3), 3.60–3.76
(3H, m, OCH2, CHOH), 4.94–4.95 (1H, m, ArCHN),
6.78–6.79 (1H, m, ArH), 7.05–7.40 (7H, m, ArH), 7.59
(2H, d, J 8.3 Hz, ArH).
CHaHb), 3.61–3.71 (2H, m, OCH2), 3.92–4.00 (1H, m,
NCH), 4.58 (1H, t, J 8.3 Hz, ArCHN), 7.17–7.35 (7H, m,
ArH), 7.62 (2H, d, J 8.0 Hz, ArH); dC (100 MHz, CDCl3)
ꢀ5.5, ꢀ5.4, 18.1, 21.6, 25.8, 33.2, 39.1, 58.5, 59.3, 62.9,
126.3, 127.8, 128.4, 128.5, 129.6, 132.2, 140.8, 143.8.
4.5.4. N-(5-(tert-Butyldimethylsilyloxy)-1-(2-chloro-
phenyl)-3-hydroxypentyl)-4-methyl benzenesulfonamide
(13yb). The general procedure described in Section 4.5
was followed to afford 13yb (162.7 mg, 65.3% from 12b)
as a white solid, mp 103–108 ꢁC. Rf (35% ethyl acetate/pe-
troleum ether) 0.44; nmax (neat): 3450, 3269, 2952, 2929,
2557, 1596, 1468, 1442, 1332, 1255, 1160, 1088, 941,
4.5.8. 2-(2-(tert-Butyldimethylsilyloxy)ethyl)-4-phenyl-1-
tosylazetidine (14ya). The general procedure described in
Section 4.5 was followed to afford 14ya (105.8 mg, 95%
from 13ya) as colorless liquid. [Found: C, 64.79; H, 7.75;
N, 3.27. C24H35NO3SSi requires: C, 64.68; H, 7.92; N,
3.14%.] Rf (10% ethyl acetate/petroleum ether) 0.34; nmax
(neat) 3063, 3031, 2954, 2927, 2884, 2856, 1598, 1494,
1471, 1460, 1388, 1343, 1304, 1287, 1255, 1158, 1094,
1028, 1006, 972, 939, 911, 882, 835, 813, 777, 735, 698,
673, 609, 547, 520 cmꢀ1; dH (400 MHz, CDCl3) 0.06 (6H,
s, CH3Si), 0.87 (9H, s, t-BuSi), 1.98–2.06 (1H, m, CHaHb),
2.32–2.40 (4H, m, ArCH3CHaHb), 2.47–2.55 (2H, m,
CH2), 3.76 (2H, t, J 5.9 Hz, OCH2), 4.53–4.59 (1H, m,
NCH), 5.21 (1H, dd, J 5.6, 8.8 Hz, ArCHN), 7.02–7.41
(9H, m, ArH); dC (100 MHz, CDCl3) ꢀ5.5, ꢀ5.4, 18.1,
21.4, 25.8, 31.9, 36.9, 59.7, 62.2, 65.2, 127.1, 127.6,
127.9, 128.2, 128.9, 136.8, 138.5, 142.5.
836, 814, 779, 756, 729, 666, 559, 460, 425 cmꢀ1
;
dH (400 MHz, CDCl3) 0.00 (6H, s, CH3Si), 0.84 (9H, s,
t-BuSi), 1.41–1.62 (4H, m, (CH2)a, (CH2)b), 2.33 (3H, s,
ArCH3), 3.59–3.79 (3H, m, OCH2, CHOH), 4.62–4.65
(1H, m, ArCHN), 7.03–7.22 (5H, m, ArH), 7.45 (1H, d,
J 7.3 Hz, ArH), 7.61 (2H, d, J 8.3 Hz, ArH).
4.5.5. N-(5-(tert-Butyldimethylsilyloxy)-3-hydroxy-1-(4-
methoxyphenyl)pentyl)-4-methyl benzenesulfonamide
(13xe). The general procedure described in Section 4.5 was
followed to afford 13xe (78.2 mg, 31.7% from 12e) as color-
less liquid. Rf (35% ethyl acetate/petroleum ether) 0.38; nmax
(neat)3482, 3278, 3054, 2953, 2929, 2856, 1733, 1653, 1612,
1558, 1540, 1513, 1463, 1440, 1361, 1321, 1304, 1265, 1250,
1177, 1158, 1091, 1036, 938, 836, 812, 779, 738, 704, 666,
565, 454, 417 cmꢀ1; dH (400 MHz, CDCl3): dH (400 MHz,
CDCl3) 0.05 (3H, s, CH3Si), 0.06 (3H, s, CH3Si), 0.89 (9H,
s, t-BuSi), 1.41–1.80 (4H, m, (CH2)a, (CH2)b), 2.36 (3H, s,
ArCH3), 3.68–3.92 (6H, m, OCH2, OCH3), 4.56–4.57 (1H,
m, ArCHN), 6.35 (1H, d, J 6.8 Hz, NH), 6.69 (2H, d,
J 8.0 Hz, ArH), 7.03 (2H, d, J 8.2 Hz, ArH), 7.13 (2H, d,
J 8.0 Hz, ArH), 7.57 (2H, d, J 8.0 Hz, ArH).
4.5.9. 2-(2-(tert-Butyldimethylsilyloxy)ethyl)-4-(2-chloro-
phenyl)-1-tosylazetidine (14xb). The general procedure
described in Section 4.5 was followed to afford 14xb
(116.4 mg, 97% from 13xb) as a white solid, mp 92–
94 ꢁC. [Found: C, 60.21; H, 7.18; N, 3.10. C24H34ClNO3SSi
requires: C, 60.04; H, 7.14; N, 2.92%.] Rf (10% ethyl ace-
tate/petroleum ether) 0.46; nmax (neat) 2953, 2928, 2857,
1596, 1467, 1439, 1379, 1349, 1255, 1163, 1085, 1026,
942, 885, 832, 754, 662, 603, 553, 465 cmꢀ1; dH
(400 MHz, CDCl3) ꢀ0.03 (3H, s, CH3Si), 0.00 (3H, s,
CH3Si), 0.83 (9H, s, t-BuSi), 1.68–1.75 (1H, m, CHaHb),
1.84–1.90 (1H, m, CHaHb), 2.15–2.22 (1H, m, CHaHb),
2.44 (3H, s, ArCH3), 2.52–2.59 (1H, m, CHaHb), 3.60–
3.66 (1H, m, OCHaHb), 3.69–3.74 (1H, m, OCHaHb),
3.93–4.00 (1H, m, NCH), 4.93 (1H, t, J 8.3 Hz, ArCHN),
7.16–7.35 (5H, m, ArH), 7.69 (2H, d, J 8.3 Hz, ArH), 7.87
(1H, d, J 7.6 Hz, ArH); dC (100 MHz, CDCl3) ꢀ5.5, ꢀ5.4,
18.1, 21.6, 25.8, 32.1, 39.3, 58.7, 59.0, 60.0, 127.0, 128.0,
128.6, 128.7, 128.9, 129.7, 131.0, 131.3, 138.7, 144.1.
4.5.6. N-(5-(tert-Butyldimethylsilyloxy)-3-hydroxy-1-(4-
methoxyphenyl)pentyl)-4-methyl benzenesulfonamide
(13ye). The general procedure described in Section 4.5 was
followed to afford 13ye (156.3 mg, 63.3% from 12e) as
a white solid, mp 105–107 ꢁC. Rf (35% ethyl acetate/petro-
leum ether) 0.31; nmax (neat) 3490, 3273, 2952, 2929,
2856, 1612, 1513, 1463, 1441, 1360, 1323, 1305, 1249,
1177, 1158, 1091, 1036, 939, 835, 812, 778, 735, 806,
666, 548, 464, 419 cmꢀ1; dH (400 MHz, CDCl3) 0.07 (6H,
s, CH3Si), 0.90 (9H, s, t-BuSi), 1.47–1.95 (4H, m, (CH2)a,
(CH2)b), 2.38 (3H, s, ArCH3), 3.71–3.86 (6H, m, OCH2,
OCH3), 4.29 (1H, dd, J 4.8, 9.7 Hz, ArCHN), 6.70 (2H, d,
J 8.5 Hz, ArH), 7.05 (2H, d, J 8.5 Hz, ArH), 7.14 (2H, d,
J 8.0 Hz, ArH), 7.55 (2H, d, J 8.0 Hz, ArH).
4.5.10. 2-(2-(tert-Butyldimethylsilyloxy)ethyl)-4-(2-
chlorophenyl)-1-tosylazetidine (14yb). The general proce-
dure described in Section 4.5 was followed to afford 14yb
(110.4 mg, 92% from 13yb) as colorless liquid. [Found: C,
60.18; H, 7.21; N, 2.95. C24H34ClNO3SSi requires: C,
60.04; H, 7.14; N, 2.92%.] Rf (10% ethyl acetate/petroleum
ether) 0.38; nmax (neat) 2955, 2929, 2856, 1597, 1470, 1441,
1346, 1257, 1158, 1092, 1035, 834, 778, 755, 668, 607, 546,
462, 416 cmꢀ1; dH (400 MHz, CDCl3) 0.06 (6H, s, CH3Si),
0.89 (9H, s, t-BuSi), 1.83–1.91 (1H, m, CHaHb), 2.19–2.26
(1H, m, CHaHb), 2.37–2.63 (5H, m, ArCH3 CH2), 3.65–
3.71 (2H, m, OCH2), 4.58–4.64 (1H, m, NCH), 5.66 (1H,
dd, J 6.8, 9.2 Hz, ArCHN), 7.19–7.42 (5H, m, ArH), 7.63–
7.69 (3H, m, ArH); dC (100 MHz, CDCl3) ꢀ5.6, 18.1,
21.5, 25.8, 32.0, 35.2, 59.7, 61.2, 62.4, 126.9, 127.6,
128.0, 128.7, 129.1, 129.4, 131.8, 136.8, 137.8, 143.3.
4.5.7. 2-(2-(tert-Butyldimethylsilyloxy)ethyl)-4-phenyl-1-
tosylazetidine (14xa). The general procedure described in
Section 4.5 was followed to afford 14xa (109.2 mg, 98%
from 13xa) as a white solid, mp 125–130 ꢁC. [Found: C,
64.61; H, 7.85; N, 3.20. C24H35NO3SSi requires: C, 64.68;
H, 7.92; N, 3.14%.] Rf (10% ethyl acetate/petroleum ether)
0.41; nmax (neat) 3030, 2953, 2927, 2884, 2855, 1598, 1494,
1471, 1386, 1346, 1304, 1289, 1256, 1161, 1092, 1018, 939,
885, 834, 812, 775, 742, 698, 665, 614, 599, 550, 527 cmꢀ1
;
dH (400 MHz, CDCl3) ꢀ0.02 (3H, s, CH3Si), ꢀ0.01 (3H, s,
CH3Si), 0.83 (9H, s, t-BuSi), 1.83–1.93 (2H, m, CH2),
2.10–2.19 (1H, m, CHaHb), 2.35–2.43 (4H, m, ArCH3,
4.5.11. 2-(2-(tert-Butyldimethylsilyloxy)ethyl)-4-(4-
methoxyphenyl)-1-tosylazetidine (14xe). The general